key: cord-0843032-zx74zzl8
authors: Lipworth, Brian J; Chan, Rory; Kuo, Chris RuiWen
title: Tocilizumab for severe COVID-19 pneumonia
date: 2020-08-17
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(20)30283-6
sha: eb9916ba68102757a74458a062947562b04f74bd
doc_id: 843032
cord_uid: zx74zzl8

nan

Severe COVID-19 manifests as a viralinduced autoimmune multiorgan disease with pneumonia, and associated cytokine-mewdiated hyperinflammation and coagulopathy. 1 A key proinflammatory cytokine involved in COVID-19 is interleukin-6 (IL-6), which induces synthesis of C-reactive protein (CRP) by hepatocytes. We read with interest the observational study by Giovanni Guaraldi and colleagues, 2 in which baseline concentrations of IL-6 and CRP, as well the PaO 2 /FiO 2 ratio, were higher in patients who received tocilizumab compared with patients who received standard of care in the Modena cohort. Moreover, 76% of patients treated with tocilizumab received concomitant glucocorticoids. 2 Prelim inary unpublished data, from a Roche press release, regarding the COVACTA trial (NCT04320615) in severe COVID-19 pneumonia have revealed futil ity for tocilizumab compared with placebo for the primary end point after 4 weeks with no difference in mortality or need for ventilation.

Herold and colleagues 3 reported on patients with severe COVID-19, showing that once IL-6 concentrations exceeded 80 pg/mL, the median time to mechanical ventilation was 1·5 days (range 0-4 days), and for CRP concentrations above 97 mg/mL, the median time to mechanical ventilation was 0 days (range 0-4 days). In another study, 4 a composite score comprising SaO 2 /FiO 2 ratio, and concentrations of CRP and IL-6 on admission, predicted clinical deterioration within 3 days of hospital admission, with an area under the receiver operating curve of 0·88. 4 Another possibility for escalating treat ment in patients with severe COVID-19 is to use medium-dose sys temic glucocorticoids to nonselectively suppress the cytokine cascade. In one study, 5 treatment with dexa metha sone at 6 mg/day in 2014 patients, compared with usual care in 4321 patients, resulted in a 35% relative reduction in mortality in ventilated patients and a 20% relative reduction in patients requiring oxygen alone.

Taken together, these observations suggest that it is time to adopt a personalised endotype-driven approach to facilitate earlier identification of patients with COVID-19 who might benefit from such selective or nonselective cytokine suppression.

CRWK reports personal fees from AstraZeneca, Chiesi, and Circassia, outside the submitted work. BJL and RC declare no competing interests

Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Prompt predicting of early clinical deterioration of moderate-to-severe COVID-19 patients: usefulness of a combined score using IL-6 in a preliminary study

Dexamethasone in hospitalized patients with COVID-19-preliminary report